The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
Globally, an estimated 20 million people developed cancer in 2022 a figure expected to increase 77% to 35 million by 2050, with poorer countries bearing the brunt, according to new data.
Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing.